Bioorganic and Medicinal Chemistry Letters p. 1416 - 1419 (2017)
Update date:2022-08-11
Topics:
Ding, Zhongpeng
Cheng, Hejuan
Wang, Shixiao
Hou, Yingwei
Zhao, Jianchun
Guan, Huashi
Li, Wenbao
Plinabulin, a drug targeting microtubule of cancer cells, has been currently tried in its phase III clinical study. However, low efficacy caused by poor pharmacokinetic (PK) properties has been considered to be the main obstacle to approved by the Food and Drug Administration. Herein, we introduced a deuterium atom as an isostere in its structure to become a new compound named (MBRI-001, No. 9 in a series of deuterium-substituted compounds). The structure of MBRI-001 was characterized by HRMS, NMR, IR and a single crystal analysis. MBRI-001 exhibited better pharmacokinetic characteristics than that of plinabulin. Additionally, its antitumor activity is in a low nanomolar level for a variety of cancer cell lines and high activity against human NCI-H460 xenograted in mice intravenous administration. Importantly, continuous administration of MBRI-001 exhibited lower toxicity compared to docetaxel. We thus suggest that MBRI-001 could be developed as a promising anti-cancer agent in near future.
View MoreContact:021-50278900
Address:No.6,Room 201 ,Lane 299,bisheng road ,shanghai ,china
website:http://www.NEM.COM.CN
Contact:+86-393-4411771
Address:The west section of shengli Road,Puyang,Henan Province,China
Shanghai Potomer International Trade CO., LTD
Contact:+86-21-61397128
Address:Room 304,No.505 ,Caoyang Road.Shanghai,China
Shanghai Massive Chemical Technology Co., Ltd.
website:http://www.massivechem.com/
Contact:+86 21 34943721
Address:Room 435, 4th floor, Building 9, No. 2568 Gudai Road,Minhang District, Shanghai,
KA-SHING Business Trade Macau Co., Ltd.
Contact:00853-28430045
Address:23rd Floor, Block 3 La Cite, Areia Preta, Macao
Doi:10.1021/jacs.7b05073
(2017)Doi:10.1007/BF00568264
()Doi:10.1016/0022-328X(90)87002-U
(1990)Doi:10.1039/c2jm33735e
(2012)Doi:10.1016/S0022-1139(00)83362-X
(1985)Doi:10.1002/cctc.201601070
(2016)